U.S. stock market midday update: Regenxbio up 8.90%, long-term effectiveness of gene therapy drives positive sentiment
I'm LongbridgeAI, I can summarize articles.Regenxbio rose 8.90%; AbbVie fell 0.61%, with a trading volume of USD 614 million; Fortress Biotech fell 1.22%, with a trading volume of USD 325 million; Amgen fell 0.55%, with a trading volume of USD 324 million; Gilead Sciences fell 0.77%, with a market capitalization of USD 165.4 billion
U.S. Stock Market Midday Update
Regenxbio rose 8.90%, with increased trading volume. Based on recent key news:
-
On July 20, Regenxbio announced it would raise approximately $100 million through a public stock offering. This issuance includes about 10 million shares of common stock and 1.11 million pre-funded warrants, with offering prices of $9 per share and $8.9999 per share, respectively. This move led to a 5.16% increase in stock price, reflecting market confidence in the company's financing capabilities. Source: Benzinga
-
On July 19, Regenxbio's gene therapy showed long-term efficacy in patients with wet age-related macular degeneration. The therapy requires only a single administration and maintains or improves patients' vision for up to 5 years, reducing the need for frequent injections and enhancing market confidence in the company's technology. Source: PR Newswire
-
On July 20, Regenxbio's technology platform was considered to have a significant position in the gene therapy field. The company provides one-time treatments for rare diseases and retinal diseases through adeno-associated virus (AAV) gene therapy, with great potential attracting investor attention. Source: TipRanks. The gene therapy industry is seeing increased attention, with significant capital inflow.
Top Stocks by Industry Trading Volume
AbbVie fell 0.61%. Based on recent key news:
-
On July 20, AbbVie relies on its main growth drivers Skyrizi and Rinvoq to achieve strong financial performance, while having several exciting pipeline candidates in the rapidly growing weight loss market. Nevertheless, the stock price still declined, possibly reflecting market concerns about its future growth. Source: Benzinga
-
On July 18, AbbVie had an annualized return of 14.83% over the past decade, outperforming the market. However, the recent decline in stock price may be related to investors reassessing its long-term growth potential. Source: Benzinga
-
No other significant news recently. The growth potential in the pharmaceutical industry remains strong.
Forte Pharma fell 1.22%. There has been no significant news from Forte Pharma recently; trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news
Amgen fell 0.55%. There has been no significant news recently; trading is active, and capital flow is evident. Considering sector and industry trends, the stock shows significant volatility, and specific reasons need further observation. no_news
Top Stocks by Industry Market Capitalization
Gilead Sciences fell 0.77%. Based on recent news,
-
On July 20, analysts raised Gilead Sciences' median EPS estimate for 2026 to -0.73, indicating increased market confidence in its profitability, driving stock price volatility. Data source: FactSet
-
On July 20th, the patent for Gilead Sciences' HIV treatment drug Biktarvy is set to expire, raising concerns in the market about its future competitiveness, leading to pressure on its stock price. Data source: CNBC.
-
No other significant news recently. Competition in HIV drugs is intensifying, and the market is paying attention